Merus N.V. is a clinical-stage company located in the Netherlands that focuses on the development of bispecific antibody therapeutics for the treatment of various cancers. Its pipeline includes several compounds in different clinical trial phases, such as Zenocutuzumab for metastatic breast cancer and MCLA-129 for advanced non-small cell lung cancer. Additionally, Merus N.V. has established partnerships with Betta Pharmaceuticals and Incyte Corporation to further research and develop its bispecific antibody candidates.